tenacious in our search for transformative therapies
TARA-002
TARA-002 is the Company’s lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for multiple oncologic indications and lymphatic malformations (LMs). We are evaluating TARA-002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and LMs in the U.S.
IV CHOLINE CHLORIDE
An investigational phospholipid substrate replacement therapy for patients on parenteral nutrition (PN). Approximately 80% of PN patients are choline deficient and have some degree of liver damage. IV Choline Chloride has the potential to become the first FDA approved IV choline formulation for PN patients.
